Abstract
IntroductionRivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual exposures exist for Asian and non-Asian populations,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have